Compare EBF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | DCTH |
|---|---|---|
| Founded | 1909 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 538.9M | 578.4M |
| IPO Year | 1994 | 2015 |
| Metric | EBF | DCTH |
|---|---|---|
| Price | $21.06 | $19.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | 139.0K | ★ 302.4K |
| Earning Date | 12-21-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.04% | N/A |
| EPS Growth | 7.79 | ★ 107.53 |
| EPS | ★ 0.76 | 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $1.01 | $24.61 |
| Revenue Next Year | $0.92 | $24.27 |
| P/E Ratio | ★ $27.43 | $374.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.33 | $8.12 |
| 52 Week High | $23.09 | $17.42 |
| Indicator | EBF | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.99 | 78.56 |
| Support Level | $20.81 | $14.14 |
| Resistance Level | $21.30 | N/A |
| Average True Range (ATR) | 0.53 | 0.68 |
| MACD | -0.17 | 0.41 |
| Stochastic Oscillator | 14.63 | 99.02 |
Ennis Inc is a trade printer company that manufactures a broad range of printed products throughout the United States. It is engaged in the business of manufacturing, designing, and selling business forms and other printed business products to distributors located in the United States. Through a network of independent distributors, its channel encompasses independent print distributors, commercial printers, direct mail, fulfillment companies, payroll and accounts payable software companies, and advertising agencies, among others. The group operates in a single reportable segment called Print and derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.